Company profile
Rockwell Medical, Inc.
NASDAQ: RMTI · Healthcare · Drug Manufacturers - Specialty & Generic
#393 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
60CFH 68DQ 52GM 45SS 71
v0.1 · 65/100 weight · provisional
↑ listing tenure, Piotroski F · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$67.7M
Rev growth YoY (TTM)
-30.7%
Net income (FY)
-$5.3M
Employees
157
as of 2026-08-21
Market cap
$30.2M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$69.3M$69.3M2025
Net income-$5.3M-$5.3M2025
Operating income-$4.7M-$4.7M2025
Total assets$57.1M$57.1M2025
Liabilities$20.2M$20.2M2025
Equity$37.0M$37.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Concentrate Products100%
By geography
UNITED STATES87%
Non-US13%
The read
What is Rockwell Medical, Inc.’s revenue?
Rockwell Medical, Inc. booked $69.3M in FY2025 revenue, contracting 32% year over year — slower than 76% of Healthcare companies we track, at a -7.7% net margin.
Peers · Healthcare
Codexis, Inc.61CBlack Diamond Therapeutics, Inc.60CPersonalis, Inc.59CVir Biotechnology, Inc.48DIntellia Therapeutics, Inc.57CKura Oncology, Inc.39DNeighbors
Oakland →Key facts
CEOMark Strobeck
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWixom, MI
ExchangeNASDAQ: RMTI
Employees157
IPO date1998-01-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.